Fact CheckerSign in

NCT06469593Recruiting

Automated Insulin Delivery for Type 1 Diabetes - Beyond Glucose Metrics

AID-BEYOND: Automated Insulin Delivery for Type 1 Diabetes - Beyond Glucose Metrics

Source: ClinicalTrials.gov · Last updated 21 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this clinical trial is to determine if transitioning to automated insulin delivery (AID) systems, can improve objectively measured sleep quality and quantity and alleviate cardiovascular risk factors in both children and adults diagnosed with type 1 diabetes. The main questions it aims to answer are: * Does the intervention improve sleep efficiency as measured by the HomeSleepTest, EEG based device, 4 months after initiation? * Can the use of AID treatment alleviate cardiovascular risk measured by heart rate variability (HRV), blood pressure and inflammatory markers? * Researchers will compare AID systems to usual treatment, including both multiple daily injections and sensor augmented pumps to see if the above benefits can be achieved with AID in comparison. Participants will be randomized 1:1 to either start AID treatment or to continue their usual care. The study will be open label. Participants will, at baseline and after 4 months: * Have taken blood and urine samples to measure metabolic and inflammatory parameters * Perform digital cognitive testing using the CANTAB software * Fill out questionnaires related to quality of life, fear of hypoglycemia, hypoglycemia awareness, eating habits and sleep quality * Wear a blinded CGM for 10 days * Monitor sleep at home using the HomeSleepTest for 3 consecutive nights * Wear a Holter monitor for 24 hours to determine HRV parameters * Measure blood pressure for 24 hours at 30 min intervals * Wear an ActiGraph for 7 days to assess sleep and activity, supported by daily electronic sleep diaries Participants randomized to AID treatment will receive education in the use of the systems. Virtual follow-up visits are scheduled at week 1, 5 and 9 for both control and intervention groups during the study, following baseline examinations.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
200 (estimated)
First submitted
11 Jun 2024
Start date
15 Jun 2024
Primary completion date
31 Dec 2025
Lead sponsor
Steno Diabetes Center Copenhagen
NCT number
NCT06469593

What you commit to

  • Study type: Interventional
  • Planned participants: 200
  • From 15 Jun 2024 to the primary completion date, 31 Dec 2025
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of commercial or open-source AID systems prior to study participation
  • Alcohol or drug abuse
  • Other concomitant medical or psychological condition that, according to the investigator's assessment, makes the person unsuitable for study participation

Other illness

  • Severe cardiac disease

Lab values

  • Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  • Retinopathy contraindicating HbA1c \<53 mmol/mol

Other

  • Daily use of paracetamol (acetaminophen)
  • Breast-feeding, pregnancy or planning to become pregnant within 4 months
  • Lack of compliance with key study procedures at the discretion of the investigator

Who the study is looking for

  • Age ≥18 years
  • Type 1 diabetes ≥3 years
  • CGM or intermittently scanned CGM (isCGM) use ≥6 months
  • Approval from the responsible health care provider (HCP) to start AID
  • Specific AID system chosen ahead of screening after participant has been thoroughly informed
  • Age 7-17 years
  • Type 1 diabetes ≥6 months
  • CGM or isCGM use ≥6 months
  • Approval from the responsible HCP to start AID
  • Specific AID system chosen ahead of screening after participant has been thoroughly informed

Age in the registry: 7 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
steno diabetes center Aarhus
Coordinator of this site? Confirm its status
AarhusDenmarkRecruiting
Steno Diabetes Center Copenhagen
Coordinator of this site? Confirm its status
HerlevDenmarkRecruiting
Diagnostisk Center, Regionshospitalet Silkeborg
Coordinator of this site? Confirm its status
SilkeborgDenmarkRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.